Nuformix PLC NXP004 Patent (1492G)
28 March 2022 - 5:00PM
UK Regulatory
TIDMNFX
RNS Number : 1492G
Nuformix PLC
28 March 2022
28 March 2022
Nuformix plc
("Nuformix" or the "Company")
NXP004 Patent
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, is pleased to announce the publication of an
international patent in relation to the Company's NXP004 asset,
which comprises novel forms of olaparib (the "Patent"). Olaparib is
currently marketed by AstraZeneca, under the Lynparza(R) brand name
for the treatment of adults with suspected deleterious germline or
somatic BRCA gene mutated ovarian, breast, or pancreatic cancer, or
for suspected deleterious germline or somatic HRR gene mutated
prostate cancer.
The application for the Patent, relating to new olaparib oxalic
acid cocrystals, their therapeutic uses and pharmaceutical
compositions containing them, was made by the Company's wholly
owned subsidiary Nuformix Technologies Limited and was filed in
September 2020. The Company filed a second patent application,
complementing the Patent, in November 2021 and this remains
pending.
The olaparib oxalic acid cocrystals covered by the Patent may be
used in the same way as olaparib. Olaparib is useful in treating
diseases that benefit from PARP (Poly ADP Ribose Polymerase)
inhibition. These include cancer, fibrosis, inflammatory conditions
(e.g. asthma, colitis, arthritis), neurological diseases (e.g.
neurodegeneration, neurotrauma, stroke), cardiovascular conditions,
ophthalmic degenerative diseases, vascular diseases (e.g. diabetic
complications, atherosclerosis), and various forms of critical
illness (e.g. septic shock, ALI, acute liver failure). The olaparib
oxalic acid cocrystals covered by the Patent may, therefore,
ultimately be useful for the treatment of such diseases, disorders,
and conditions.
The Company looks forward to providing further updates on
progress with NXP004 and the Company's other assets in due
course.
Commenting, Alastair Riddell, Executive Chairman of Nuformix,
said: "We are pleased to see the progression of the application for
the Company's first patent in relation to NXP004 to the publication
stage. We believe NXP004 has significant potential and look forward
to the granting of the Patent in due course. We are continuing to
conduct further research and development activities on NXP004, as
well as investigating future commercial opportunities. Whilst there
remains much to be done, I look forward to making further
announcements on our progress in the future."
Enquiries:
Nuformix plc
Dr Alastair Riddell, Executive Chairman Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with
potential for significant value and early licensing
opportunities.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCLDLFLLXLLBBK
(END) Dow Jones Newswires
March 28, 2022 02:00 ET (06:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024